Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program

PharmacoEconomics

Volumn 32, Issue 3, 2014, Pages 245-255

  Chen, Mingsheng ^a   Wang, Lijie ^a   Chen, Wen ^a   Zhang, Luying ^a   Jiang, Hongli ^a   Mao, Wenhui ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ESSENTIAL DRUG;

ARTICLE; BRONCHITIS; CHINA; CHINESE MEDICINE; CONTROLLED STUDY; CORONARY ARTERY; DIABETES MELLITUS; ECONOMIC ASPECT; EXPERIENCE; GASTRITIS; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICINE; PHYSICIAN; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PUBLIC HEALTH; REIMBURSEMENT; UPPER RESPIRATORY TRACT INFECTION; CLINICAL PRACTICE; DRUG USE; ECONOMICS; STATISTICS AND NUMERICAL DATA;

CHINA; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DRUGS, ESSENTIAL; HEALTH CARE REFORM; HEALTH POLICY; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84896273278     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0068-z     Document Type: Article

References (38)

1. Jassim Al Khaja KA, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Int J Clin Pharmacol Ther. 2000;38(12):568-80.
2. World Health Organization. Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. Geneva: WHO; 2009.
3. Shivhare SC, Kunjwani HK, Manikrao AM, et al. Drugs hazards and rational use of drugs: a review. J Chem Pharm Res. 2010;2(1):106-12.
4. International Prescrire. A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int. 2003;12:74-7.
5. Sara B, Jonathan DQ, Germán V. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva: WHO; 1997.
6. World Health Organization. Promoting rational use of medicines: core components. In: WHO policy perspectives on medicines. Report no. 5. Geneva: WHO; 2002.
7. Hsiao WC. The political economy of Chinese health system reform. Health Econ Policy Law. 2007;2(Pt 3):241-9.
8. China National Health Economics Institute. China national health accounts report 2009. Beijing: Ministry of Health; 2009.
9. Hu S, Chen W, Cheng X, et al. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy Plan. 2001;16(Suppl. 2):4-9. (Pubitemid 34083957)
10. Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific Region. Value in Health. 2008;11(Suppl. 1):124-9.
11. Yang L. The essential medicine system in China: strategies and challenges (abstract). Value Health. 2010;533.
12. Ho LS. Market reform and China's health care system. Soc Sci Med. 1995;41(8):1065-72.
13. Jiang Qian, Nancy Yu B, Ying G, et al. Outpatient prescription practices in rural township health centers in Sichuan province, China. BMC Health Serv Res. 2012;12(1):324.
14. Liang Xiaoyun, Jin Chenggang, Wang Li, et al. Unnecessary use of antibiotics for inpatient children with pneumonia in two counties of rural China. Int J Clin Pharm. 2011;33(5):750-4.
15. Eggleston K, Ling L, Qingyue M, et al. Health service delivery in China: a literature review. Health Econ. 2008;17(2):149-65. (Pubitemid 351265992)
16. Yu X, Li C, Shi Y, et al. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy. 2010;97(1):8-15.
17. Chen W, Tang SL, Sun J, et al. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211-8.
18. Sun X, Jackson S, Carmichael GA, Sleigh AC. Prescribing behaviour of village doctors under China's New Cooperative Medical Scheme. Soc Sci Med. 2009;68:1775-9.
19. Yip W, Hsiao WC. Market watch: the Chinese health system at a crossroads. Health Affairs. 2008;27:460-8. (Pubitemid 351490339)
20. Yao KH, Yang YH. Streptococcus pneumonia diseases in Chinese children: past, present and future. Vaccine. 2008;26(35):4425-33.
21. Li J, Ma Y, Wang Z, et al. Klebsiella pneumonia: epidemiology and analysis of risk factors for infections caused by resistant strains. Chin Med J. 2002;115(8):1158-62. (Pubitemid 34947333)
22. Dong L, Yan H, Wang D. Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China. J Antimicrob Chemother. 2008;62(2):410-5. (Pubitemid 351984790)
23. Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28(1):63-7.
24. Chen Z. Launch of the health-care reform plan in China. Lancet. 2009;373:1322-4.
25. Li Q, Zeng FD. The necessity to develop the national drug policy in our country (in Chinese). Chin J Pharmaco Epidemiol. 2003;12(6):281-5.
26. International Network for Rational Use of Drugs. How to investigate drug use in health facilities: selected drug use indicators. Geneva: WHO; 1993.
27. Meng Q, Xu L, Zhang YG, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805-14.
28. Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China's New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-indifference analysis. BMJ. 2010;341:1-9.
29. Couper MC, Mehta D. WHO model formulary. Geneva: WHO; 2002.
30. Ministry of Health China. Prescription Administrative Policy, 2007 (online). http://www.gov.cn/flfg/2007-03/13/content-549406.htm. Accessed 9 Dec 2012.
31. Carandang ED. Rational drug use: Philippine experience. In: Chaudhury RR, Somrongthorn, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1999.
32. Chetley A, Rohde JE. National drug policies as the first step towards rational drug use: the experience of Bangladesh. In: Chaudhury RR, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1994.
33. Chaudhury RR, Parameswar R, Gupta U, et al. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy Plan. 2005;20(2):124-36. (Pubitemid 40395685)
34. World Health Organization. Promoting rational use of medicines: core components. Geneva: WHO; 2002.
35. Bank World. Financing, pricing, and utilization of pharmaceuticals in China: the road to reform. Washington, DC: World Bank; 2010.
36. Figueiras A, Sastre I, Gestal-Otero JJ. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. J Eval Clin Pract. 2001;7(2):223-41. (Pubitemid 32489014)
37. Mandal SC, Mandal M. Improving use of medicines in the community through interventions. Value Health. 2011;14(7):A340.
38. Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64(1):151-8.